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The aim of this study was to evaluate over time circulating γδ T lymphocytes in melanoma
patients in terms of frequency, effector functions, and relationship with clinical stage and
evolution, by comparing preoperative values to those obtained at a mean follow-up of 36
months or in the event of recurrence or disease progression, and to those of healthy con-
trols. Also, we correlated the presence of tumor-infiltrating γδ T lymphocytes with clinical
evolution of melanoma.
Results
Mean frequencies of circulating γδ T cells before and after melanoma removal were very
similar and comparable to healthy subjects, but patients who progressed to stage III or IV
showed a significantly decreased frequency of circulating Vγ9Vδ2 T cells. The distribution
of Vγ9Vδ2 memory and effector subsets was similar in healthy subjects and melanoma
patients at diagnosis, but circulating γδ T cells of patients after melanoma removal had a
skewed terminally-differentiated effector memory phenotype. Highly suggestive of progres-
sive differentiation toward a cytotoxic phenotype, Vγ9Vδ2T cells from patients at follow up
had increased cytotoxic potential and limited cytokine production capability, while the oppo-
site pattern was detected in Vγ9Vδ2T cells from patients before melanoma removal.
Conclusions
Follow-up data also showed that tumor infiltrating γδ T cells were significantly associated
with lower mortality and relapse rates, suggesting that they may serve as a prognostic bio-
marker, for human melanoma.
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Introduction
Malignant melanoma accounts for only 3% of cutaneous tumors, but shows high tendency to
metastasize and is responsible for as much as 65% of death for skin cancers [1]. While the stan-
dard treatment for localized melanoma is surgical resection, the treatment of metastatic mela-
noma is still challenging and carries a significant treatment-related morbidity; advanced
disease is still associated with a poor prognosis and further research is needed to provide more
effective and tolerable therapeutic protocols for stage III and IV melanoma [2–4].
In the last 40 years, increasing interest has developed toward host cellular immune response
and its possible therapeutic implication in the adjuvant therapy and advanced disease settings.
Spontaneous regression of disease has been reported in patients with melanoma, suggesting a
role for host immunity [5], which is indirectly supported by the evidence for lymphocyte infil-
tration of primary melanomas associated with tumor regression [6,7].
Tumor-infiltrating lymphocytes (TILs) have been shown to play an important role in the
anti-tumor surveillance and have been documented in a wide variety of solid tumors including
melanoma, breast, renal cell, prostate and colon cancers [8–10]. A potential prognostic and
predictive significance has been suggested [11] and numerous clinical trials have focused on
their possible use in adoptive immunotherapy [11–15]. CD4+ and CD8+ T cells are often
reported as the predominant subset of lymphocytes within TILs [16–18] and currently repre-
sent a common target for adoptive immunotherapy [19,20]. However, increasing evidence
exists for a role of γδ T lymphocytes in the anti-tumor surveillance in the periphery [21], which
is supported by their localization within epithelia. γδ T lymphocytes can be distinguished into
two subsets: those expressing the Vδ1 chain are a minor population in the peripheral blood but
predominate in mucosal tissues [22], while the subset expressing the Vδ2 chain paired to the
Vγ9 chain (here and after referred to as Vγ9Vδ2 T cells) predominates in peripheral blood and
lymphoid tissues in human adults [22]. Vγ9Vδ2 T cells recognize non-peptidic antigens (phos-
phoantigens, PAgs) by a MHC-unrestricted mechanism [23,24] and typically perform anti-
tumor immune responses (cytotoxicity, production of IFN-γ and TNF-α, and dendritic cell
maturation) [25,26]. Thus, there is a substantial interest in γδ T cells in the context of immuno-
therapeutic strategies and several pilot studies have described a partial success of γδ T cell-
based immunotherapy in different types of cancer after the application of aminobisphospho-
nates (n-BP) or PAgs plus IL-2 in vivo or after repetitive transfer of in vitro expanded Vγ9Vδ2
T cells [27,28].
In a recent study, we have demonstrated that γδ T lymphocytes are well represented
amongst TILs in cutaneous melanomas, produce the pro-inflammatory cytokines TNF-α and
IFN-γ and exert a strong cytotoxic activity against melanoma cells in vitro [29]. Strongly sug-
gestive of their anti-tumor role, percentages of Vγ9Vδ2 T cells, but not total γδ or Vδ1 T cells,
correlate with early stage of melanoma and absence of metastasis.
In this study, we have investigated the diagnostic and prognostic potential of a Vγ9Vδ2 T-
cell-based blood analysis on the grounds, that it may provide a useful biomarker of the patient’s
anti-tumor immune response. To this aim, we have evaluated circulating Vγ9Vδ2 T lympho-
cytes in terms of frequency, effector functions and relationship with clinical stage and evolution,
in subjects before and after removal of melanoma, and compared them with healthy controls.
Materials and Methods
Characteristics of the study cohort and study design
In this study, we enrolled patients from the same cohort of patients of our previous study on
cutaneous melanoma and γδ T lymphocytes [29]. The cohort consisted of 74 patients with
γδ T Cells during Melanoma Follow-Up
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histologically confirmed diagnosis of cutaneous melanoma, treated between March 2007 and
March 2010 at the Plastic Surgery Unit of the University of Palermo. Forty-two patients were
males and thirty-two were females; median age at surgery was 60 years (range 26–90). Sixty-
nine patients (93%) presented with primary cutaneous melanoma and 5 patients with cutane-
ous or subcutaneous metastases (7%). All patients were staged according to the new American
Joint Committee on Cancer staging system for cutaneous melanoma [30]. Patients were fol-
lowed in a multidisciplinary melanoma clinic at the University of Palermo, and disease related
mortality and relapse rates were recorded. Data were complemented with those obtained at a
mean follow-up of 36 months. A blood sample was obtained from 38 out of 74 patients at the
time of diagnosis and a second blood sample was obtained from 32 out of these 38 patients at
the follow-up, or in the event of recurrence or disease progression. The clinicopathologic char-
acteristics of the study cohort are given in Table 1. Blood samples from 45 age- and sex-
matched healthy subjects in good and stable clinical condition, with laboratory parameters in
the physiologic range, were used as a control.
Ethics Statement
The study was approved by the Ethical Committee of the University Hospital, Palermo, where
the patients were recruited. The study was performed in accordance to the principles of the
Table 1. Clinicopathologic characteristics of the study cohort.





Primary melanoma 31 (96.9)
Cutaneous/subcutaneous metastasis 1 (3.1)
Melanoma subtype





Head and neck 3 (9.4)
Trunk 15 (46.9)
Upper limb 3 (9.4)
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Helsinki declaration and those of the “Good Clinical Practices”, and all individuals gave written
informed consent to participate.
Isolation of PBMC and tumor-infiltrating immune cells, and FACS
analysis
Peripheral blood mononuclear cells (PBMC) were obtained by density gradient centrifugation
using Ficoll-Hypaque (Pharmacia Biotech, Uppsala, Sweden). Tissue specimens were obtained
from 74 different patients undergoing standard-of-care surgical procedures for cutaneous mel-
anoma, at the time of primary surgery. There were no restrictions (e.g. stage, etc) on tissues
included for this study other than confirmation of melanoma by pathology review of H&E
slides from the specimen taken for research. Tissue was obtained fresh and immediately trans-
ported to the laboratory in sterile saline for processing. Tissue was first minced into small
pieces followed by digestion with collagenase type IV and DNAase (Sigma, St. Louis, MO) for 1
hr at 37°C. After digestion, the cells extracted were washed twice in RPMI 1640 medium
(Gibco, Grand Island, NY, USA) and tumor-infiltrating mononuclear cells were obtained by
Ficoll-Hypaque density gradient centrifugation. Both PBMC and tumor-infiltrating cells were
stained for live/dead discrimination using Invitrogen LIVE/DEAD fixable violet dead cell stain
kit (Invitrogen, Carlsbad, CA). Fc receptor blocking was performed with human immunoglob-
ulin (Sigma, 3 μg/ml final concentration) followed by surface staining with different fluoro-
chrome-conjugated antibodies to study the composition of the different subpopulations.
The fluorochrome-conjugated monoclonal antibodies (mAbs) used to characterized the
entire population were the following: anti-CD45, anti-CD3, anti-CD14, anti-CD19, anti-pan
γδ TCR, anti-Vδ1, anti-Vδ2, anti-CD27 and anti-CD45RA, all purchased from BD Biosciences
(Mountain View, CA). Expression of surface markers was determined by flow cytometry on a
FACSCanto II Flow Cytometer with the use of the FlowJo software (BD Biosciences). The cells
were first gated for singlets (FSC-H vs FSC-A), then for lymphomonocytes (SSC-A vs FSC-A)
and then for T lymphocytes (CD45 vs CD3). The T lymphocyte gate was further analyzed for
uptake of the LIVE/DEAD stain to determine live versus dead cells and their expression of
CD14 and CD19, taking only the live, healthy T cell population (L/D-/low,CD14-, CD19-). Pan-
γδ TCR, Vδ1, Vδ2, CD27 and CD45RA cell surface expression was then determined from this
gated population. For every sample at least 100.000 viable lymphomonocytes were acquired.
Negative control (background) values were not subtracted, as the median backgrounds for iso-
type-matched mAbs was 0.0028% (range, 0.000%-0.0063%). Samples were considered positive
if the number of cells was equal to or greater than 0.01% and at least 10 clustered events were
apparent. This empiric cut-off value was predicted to be> 90% different from background, at
an α of 0.05 [29,31].
Flow cytometry-based γδ T cell functional assays
PBMC were resuspended at a concentration of 5x106/ml in complete RPMI medium in the
presence of Zoledronate (Novartis Pharma, Basel, Switzerland, 1 μM) or with PMA (BD Biosci-
ences, 20 ng/ml) and ionomycin (BD Biosciences, 1 μM). Anti-CD107a/b mAb (BD Biosci-
ences) was directly added to the culture at this time point [26]. Two hours after stimulation,
Monensin (Sigma, 2 μM) was added and the cells were incubated overnight at 37°C in 5% CO2.
Then PBMC were stained with anti-TCR Vδ2 and anti-CD3 mAbs for 15 min at 4°C. Samples
were fixed, permeabilized according to manufacturer’s instructions and incubated with anti-
IFN-γ (25723.11, BD Biosciences, Mountain View, CA), anti-perforin (δG9, Vinci-Biochem,
Firenze, Italy) or anti-Granzyme B (GB11, BD Biosciences) mAbs or isotype-matched control
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mAbs, for 30 min at 4°C. After washing, the expression of surface CD107a/b and intracellular
IFN-γ, perforin or Granzyme B was analyzed upon gating on the Vδ2+ T cell population.
Statistical analysis
Statistical analysis was performed using the SPSS 20.0 software. The frequencies of circulating
γδ T lymphocytes (preoperative values, follow-up values, healthy controls) were compared
using nonparametric tests (Wilcoxon test, Mann Whitney test), based on the type of data and
the sample size. Mortality and relapse rates in patients with and without tumor-infiltrating
Vδ2 T lymphocytes at first diagnosis were compared using Chi squared test with Yates’ correc-
tion. Differences between groups with a p value 0.05 were regarded as significant.
Results
Ex vivo analysis of γδ T lymphocytes after melanoma removal
PBMC from 32 subjects were collected before surgical removal of a primary cutaneous mela-
noma and at a median follow-up of 36 months and were analyzed for the percentage of γδ T
cells. The results were compared with those in a group of 45 sex- and age-matched healthy sub-
jects (HS) used as control. As shown in Fig 1, the percentages of total γδ T cells (A) and their
Vδ1 (B) and Vγ9Vδ2 (C) subsets were similar in melanoma patients before and after tumor
removal and comparable to frequencies detected in HS, with no statistically significant differ-
ences between the three tested groups.
Phenotypic and functional γδ T cell responses after melanoma removal
Human Vγ9Vδ2 T cells include those with naive or central-memory phenotypes (Tnaive,
CD45RA+CD27+; TCM, CD45RA
-CD27+) that home to secondary lymphoid organs, but that
lack immediate effector function, and those with effector-memory (TEM, CD45RA
-CD27-) and
terminally-differentiated (TEMRA, CD45RA
+CD27-) phenotypes that home to sites of inflam-
mation and that display immediate effector functions as cytokine production and cytotoxic
activity [32]. The phenotype and the functional responses of Vγ9Vδ2 T cells were analyzed
before and at follow-up after melanoma removal and compared to those observed in healthy
subjects.
As shown in Fig 2A, Vγ9Vδ2T cells obtained from PBMC of HS and melanoma patients
before tumor removal showed a similar subset distribution with predominance of the TCM
(76.8% and 69.6%, respectively) and the TEM (13% and 21%, respectively) phenotypes, which
together accounted for approximately 90% of the whole Vγ9Vδ2 compartment. Conversely,
TNaive and TEMRA subsets were very poorly represented amongst circulating Vγ9Vδ2 T cells of
HS and patients before melanoma removal. As shown in Fig 2A, the majority of circulating
Vγ9Vδ2 T lymphocytes in patients at follow up after melanoma removal expressed the TEMRA
phenotype, while the other three subsets were poorly represented.
This skewed phenotype of peripheral Vγ9Vδ2 T cells was strikingly depicted by the raw
data for patient #7 shown in Fig 2B. Overall, the statistically significant changes in circulating
Vγ9Vδ2T cell subset distribution indicate that a long-term effector maturation and mobiliza-
tion of peripheral blood Vγ9Vδ2 T cells occur in subjects after melanoma removal and evoke
previous observations after Zoledronate injection in cancer patients [33,34].
The phenotypic modifications of Vγ9Vδ2 T cells in subjects at follow up after melanoma
removal were paralleled by modifications in their functional responses in vitro. Analysis per-
formed in 14 patients showed (Fig 3A), that intracellular IFN-γ response to Iomomycin/PMA
stimulation declined over time after melanoma removal, as compared to the response observed
γδ T Cells during Melanoma Follow-Up
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Fig 1. Percentages of total γδ T cells (A) and their Vδ1 (B) and Vγ9Vδ2 (C) subsets in healthy subjects
and in melanoma patients before and after tumor removal. Box plots of percentages of γδ T cells subsets
in 32 melanoma patients before and after melanoma removal and in 45 healthy subjects. Boxes represent
25th to 75th percentiles; middle bar identifies median; whiskers showminimum and maximum.
doi:10.1371/journal.pone.0149570.g001
Fig 2. Phenotype of circulating Vγ9Vδ2 T cells before and after melanoma removal. PBMC were stained with anti-CD3, anti-Vδ2, anti-CD45RA and
CD27 mAbs. Percentages of Tnaive (CD45RA
+CD27+), TCM (CD45RA
-CD27+), TEM (CD45RA
-CD27-) and TEMRA (CD45RA
+CD27-) cells were determined by
FACS analysis. (A) Shows cumulative data for Vδ2 T cells and (B) shows representative flow cytometry panels from patient # 7 upon gating on CD3+Vδ2+ T
cells and staining with CD27 and CD45RA.
doi:10.1371/journal.pone.0149570.g002
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Fig 3. Functional responses of circulating Vγ9Vδ2 T cells in patients before and after melanoma
removal. (A) Cumulative data and of intracellular IFN-γproduction and CD107a mobilization assays upon in
vitro stimulation with Zoledronate or Iomomycin/PMA. (B) and (C) show raw data of intracellular IFN-
γproduction and CD107a mobilization (B) and intracellular perforin and granzyme B expression by Vγ9Vδ2 of
patient #21.
doi:10.1371/journal.pone.0149570.g003
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in the same patients before melanoma removal; IFN-γ response to Zoledronate stimulation
also decreased after melanoma removal, but differences did not attain statistical significance.
Conversely, the cytotoxic capability of Vγ9Vδ2 T cells (measured by the CD107 mobilization
assay after Iomomycin/PMA or Zoledronate stimulation) consistently increased in patients
after melanoma removal, and differences to values in patients before melanoma removal
attained statistical significance. In accordance with the CD107a mobilization results, intracellu-
lar FACS analysis carried out on Vγ9Vδ2 T cells from 4 patients after melanoma removal
revealed increased expression of perforin (70.3 ± 8,6% versus 25.3 ± 6.1%) and granzyme B
(79.5 ± 10.4% versus 28.7 ± 6.7%). This trend is illustrated by raw data for patient #21 (Fig 3B
and 3C).
Correlation between circulating Vγ9Vδ2 T cells and clinical outcomes
Twelve out of the 32 studied patients relapsed and progressed after melanoma removal; six of
them died before another blood sample was collected and thus follow-up data are available for
only 6 patients, who progressed to stage III (1 patient) or stage IV (5 patients). Progression was
invariably associated to substantial declines in Vγ9Vδ2 T cell numbers: as shown in Fig 4,
patients who progressed to stage III or IV showed a decreased frequency of circulating Vγ9Vδ2
T cells at 36-months follow-up compared to values at diagnosis (4.55% to 1.81%). Conversely,
patients who did not progress during the follow-up period showed a sustained or slightly
increased frequency of circulating Vγ9Vδ2 T cells over time (2.94% to 3.15%). The Wilcoxon
test for paired data showed a significant difference between preoperative and follow-up values
in the “progressor” group of patients (p = 0.02), but not in the “non progressor” group
(p = 0.39). Also, the MannWhitney test showed a significant difference in the frequency varia-
tion over time between the “progressor” and “nonprogressor” groups (p = 0.01).
Correlation of circulating and intratumoral Vγ9Vδ2 T cells with
clinicopathological parameters of melanoma
To investigate further the clinical significance of Vγ9Vδ2 T cells in melanoma, the percentages
of circulating and tumor-infiltrating Vγ9Vδ2 T cells at the time of diagnosis were analyzed rel-
ative to clinicopathological factors of melanoma patients, including cancer-specific survival
rates, relapse-free survival (RFS) and overall survival (OS). We observed no statistically signifi-
cant associations between the percentage of circulating Vγ9Vδ2 T cells before melanoma
removal and stage, RFS and OS (data not shown). We then determined the impact of tumor-
Fig 4. Percentages of Vγ9Vδ2 T cells in “progressor” and “not progressor” groups of melanoma patients and in healthy subjects. Boxes represent
25th to 75th percentiles; middle bar identifies median; whiskers showminimum and maximum.
doi:10.1371/journal.pone.0149570.g004
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infiltrating Vγ9Vδ2 T cells on survival rates in a cohort of 74 previously studies melanoma
patients [29] to determine the prognostic significance of intratumoral Vγ9Vδ2T cells. Previ-
ously, we reported that the presence of Vγ9Vδ2 T cells among tumor-infiltrating lymphocytes
was positively correlated with earlier tumor stages (0, I and II). As shown in Table 2, the pres-
ence of Vγ9Vδ2 T cells among tumor-infiltrating lymphocytes was positively correlated not
only with stage, but also with RFS and OS of melanoma patients: at a median follow-up of 36
months, the relapse rate was 13.0% when Vγ9Vδ2 T cells were present, and 35.7% in the
absence of Vγ9Vδ2 T cells (Table 2). Similarly, the mortality rate was 21.4% in the absence of
Vγ9Vδ2 T cell infiltration, but 0% when Vγ9Vδ2 T cells were present. The Chi squared test
with Yates’ correction showed a significant difference between the “γδ positive” and “γδ nega-
tive” groups in both the mortality rate (p = 0.005) and the disease relapse rate (p = 0.045).
Discussion
γδ T cells possess a combination of innate and adaptive immune cell qualities rendering them
attractive for immunotherapy [21]. Two recent surveys [27,28] have reviewed the available
published studies on the in vivo activation and adoptive transfer of ex vivo- expanded γδ T cells
in cancer patients, providing evidence that Vγ9Vδ2 T cell-based immunotherapy improves
overall survival and, in view of its low toxicity grade, provides a proof of principle for its utiliza-
tion as adjuvant to conventional therapies for resistant/refractory patients care. Although γδ T
cell-based immunotherapy has delivered promising results, several factor influence its success,
amongst which is the finding of a low number and/or functionally unresponsive γδ T cells in
patients with several types of tumors ([21,35]). For instance, Provinciali et al. [36,37] found
that the number of circulating γδ T cells and their Vγ9Vδ2 subset was reduced in patients with
melanoma and was not recovered after melanoma removal, as compared to the levels found in
controls. However, Vγ9Vδ2 T cells had increased proliferative and cytokine-producing capabil-
ity after melanoma removal, in comparison with the same subjects before surgical intervention
or with control donors. Conversely, Petrini and coworkers [38] have found similar percentages
of circulating γδ T cells in healthy control subjects and patients with melanoma, which had
normal proliferative capacity but impaired cytotoxic activity, and Campillo et al. found
increased frequencies of γδ T cells in patients with melanoma, which had high perforin content
[39]
In this paper, we have evaluated the frequencies and functional properties of circulating
Vγ9Vδ2 T lymphocytes in subjects before and after removal of melanoma, in relationship with
clinical stage and evolution, and compared them with healthy controls. Data here reported
clearly show that percentages of total γδ T cells and their Vδ1 and Vγ9Vδ2 subsets did not
Table 2. Correlations between tumor-infiltrating Vγ9Vδ2 T cells and clinicopathologic characteristics
in melanoma patients.
Vγ9Vδ2 T cells amongst TILs
Parameter + (n = 46) - (n = 28) p value
Stage
0-I-II 68% 32% 0.035
III-IV 29% 71% 0.025
Mortality rate 0% 21.4% 0.005
Relapse rate 13% 35.7% 0.045
Mortality and relapse rate among 74 patients with cutaneous melanoma (median 36 months follow-up).
doi:10.1371/journal.pone.0149570.t002
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significantly differ in melanoma patients before and after tumor removal and in healthy control
subjects. We do not have any explanation for the difference between our results and the previ-
ously reported γδ T cell studies in patients with melanoma. One possibility might be that
changes in Vγ9Vδ2 T cell numbers and functions might be age- and sex-related and not a con-
sequence of tumor growth. Accordingly, Vγ9Vδ2 T cells change characteristically with age,
gradually decreasing beyond 30 years of age and drop more strikingly in men than in women
[40]. Moreover, this loss is accompanied by a substantial depletion of Vγ9Vδ2 effector T cells,
which is mirrored by a reduced IFN-γ secretion [40]. Accordingly, the absolute number of
Vγ9Vδ2 T cells in a cohort of breast cancer patients receiving chemotherapy did not differ
from age-matched breast cancer patients without treatment [41] and the decrease in absolute
numbers of Vγ9Vδ2 T cells in a cohort of 41 patients with pancreatic ductal adenocarcinoma
did not correlate with cancer stage/progression, but rather with patient age [42].
While we did not find any statistically significant difference in the distribution of Vγ9Vδ2
memory and effector subsets between healthy subjects and melanoma patients, lymphocytes
expressing the TEMRA phenotype were the dominant Vγ9Vδ2 T cell subset in patients at fol-
low-up after melanoma removal. Highly suggestive of progressive differentiation toward a
cytotoxic phenotype, Vγ9Vδ2 T cells from patients at follow-up had increased cytotoxic poten-
tial and limited cytokine production capability. Whether or not this predominant Vγ9Vδ2
TEMRA phenotypic and functional status is associated with clinically relevant melanoma fea-
tures is actually unknown. Intuitively, the accumulation of antigen-experienced Vγ9Vδ2
TEMRA cells with a powerful cytotoxic potential could be considered beneficial in terms of dis-
ease control. However, recent studies in patients with chronic lymphatic leukemia have dem-
onstrated that elevated numbers of circulating Vγ9Vδ2 T cells with dominant TEM and TEMRA
phenotypes are a negative prognosticator [43], which is reminiscent of data previously reported
in conventional CD4+ and CD8+ cells [44,45]; in these patients, TEMRA CD8
+ cells displayed
the phenotypic hallmarks of functional exhaustion, further supporting the concept that long-
lasting tumor-induced chronic activation may lead to the undesired accumulation of cells
unable to exert effective antitumor activity. Indeed, several in vitro and in vivo data indicate
that chronic Vγ9Vδ2 T cell activation may induce functional exhaustion or anergy. Anergy has
been reported in HIV-infected individuals [46], whereas functional exhaustion has been
described in a preclinical nonhuman primate model after repeated stimulations with PAgs and
low-dose IL-2 [47] and has been associated with a differentiation shift, which is well in line
with the accumulation of Vγ9Vδ2 TEMRA cells.
In our study, we also evaluated the impact of baseline and follow-up Vγ9Vδ2 T cell counts
on clinicopathological parameters of melanoma, to investigate whether these counts could be
used as an alternative to predict outcome. While baseline percentages of circulating Vγ9Vδ2 T
cells were not significantly correlated to any of the well established prognostic factors for mela-
noma (stage, RFS and OS), progression was invariably associated to substantial declines in
Vγ9Vδ2 T cell numbers, reminiscent of our previous observations after Zoledronate and IL-2
injection in cancer patients.
We further determined prognostic significance of tumor-infiltrating Vγ9Vδ2T cells for the
prediction of cancer development during the follow-up period in a cohort of 74 previously
studies melanoma patients, and we show here that the presence of Vγ9Vδ2 T cells among
tumor-infiltrating lymphocytes was positively correlated with RFS and OS of melanoma
patients.
In this regard, our study, albeit small, emphasizes strongly a correlation of peripheral blood
Vγ9Vδ2 T cells with arrested disease progression, and this evokes a comparable correlation of
Vγ9Vδ2 T cell numbers (and most likely activities) with arrested disease progression in other
scenarios of advanced malignancy [33,48]. We note, however, that the declining health of
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patients could not be attributed to poor functional conversion of Vγ9Vδ2 T cells (which was
equivalent in all patients, data not shown). Therefore, the critical difference seems to be a fail-
ure to sustain robust Vγ9Vδ2 T cell numbers, implying that high response frequencies
compose a key property of lymphoid stress-surveillance [8]. Hence, any future treatment opti-
mizations should respect the need to achieve sufficiently large numbers of relevant Vγ9Vδ2 T
cells.
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